| Name | Title | Contact Details |
|---|
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.
BioVir Laboratories is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bioinformatics Solutions Inc. is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.